Travere Therapeutics (TVTX) Other financing activities (2014 - 2026)

Travere Therapeutics (TVTX) has 13 years of Other financing activities data on file, last reported at $4.7 million in Q1 2026.

• Quarterly Other financing activities rose 11.45% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.2 million (up 730.33% YoY) and the FY2025 annual result came in at $34.7 million, changed N/A from the prior year.
• Other financing activities retreated to $4.7 million in Q1 2026, from $25.9 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $25.9 million in Q4 2025 to a low of -$4.2 million in Q3 2023.
• A 5-year average of $2.7 million and a median of $1.3 million in 2024 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 4644.48% in 2025, down 307.04% in 2025.
• Tracing TVTX's Other financing activities over 5 years: stood at -$4.0 million in 2022, then surged by 207.01% to $4.3 million in 2023, then tumbled by 113.31% to -$571000.0 in 2024, then soared by 4644.48% to $25.9 million in 2025, then tumbled by 81.78% to $4.7 million in 2026.
• The last three Other financing activities figures came in at $4.7 million (Q1 2026), $25.9 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.